Become a Member to Save

LIVTENCITY▼® (maribavir) safety data

An overview of the safety and tolerability profile of LIVTENCITY

A discussion of the outcomes of the phase III SOLSTICE trial featured in this video:
Dr Sowsan Atabani (Consultant Virologist, UK Health Security Agency and University Hospitals Birmingham)
Mr Colin Wilson (Consultant Transplant and Hepatobiliary Surgeon, Newcastle Hospitals)

LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).1
Consideration should be given to official guidance on the appropriate use of antiviral agents.1

Book a meeting

Click this link to discuss the information on this page further with a Takeda representative.

In the SOLSTICE trial, LIVTENCITY delivered double the viraemia clearance (55.7%) compared to investigator-assigned therapy (IAT) (23.9%) – primary endpoint2

Confirmed viraemia clearance* of refractory CMV in all transplants (HSCT and SOT) at Study Week 82

*Plasma CMV DNA <137 IU/mL in 2 consecutive tests ≥5 days apart.2

LIVTENCITY — positive safety profile in post-transplant refractory CMV (with or without resistance)

Fewer treatment emergent adverse events leading to discontinuation than IAT: 13.2% [31/234] of transplant recipients treated with LIVTENCITY experienced a TEAE that led to discontinuation (vs 31.9% [37/116] in those who received investigator assigned therapies)3

LIVTENCITY treatment-related adverse events compared to IAT2,3

In the SOLSTICE trial, the most reported treatment-related adverse event was dysgeusia (35.9% [84/234] vs 0.9% [1/116] receiving IAT) that typically resolved during or after treatment.3